U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H23FN4O8
Molecular Weight 441.3982
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIFLUFOLASTAT F-18

SMILES

OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)C1=CC=C([18F])N=C1)C(O)=O)C(O)=O

InChI

InChIKey=OLWVRJUNLXQDSP-MVBOSPHXSA-N
InChI=1S/C18H23FN4O8/c19-13-6-4-10(9-21-13)15(26)20-8-2-1-3-11(16(27)28)22-18(31)23-12(17(29)30)5-7-14(24)25/h4,6,9,11-12H,1-3,5,7-8H2,(H,20,26)(H,24,25)(H,27,28)(H,29,30)(H2,22,23,31)/t11-,12-/m0/s1/i19-1

HIDE SMILES / InChI

Molecular Formula C18H23FN4O8
Molecular Weight 441.3982
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

DCFPYL F-18 is an urea-based radiotracer composed of the prostate-specific membrane antigen (PSMA)-targeting agent DCFPyL and labeled with the positron-emitting isotope, fluorine F 18, that can potentially be used for positron-emitting tomography (PET) imaging. Upon administration of fluorine F 18 DCFPyL, the DCFPyL moiety binds to PSMA expressed on tumor cells. The fluorine F 18 moiety facilitates PET imaging of PSMA-expressing tumor cells. DCFPYL F-18 is investigated in a number of clinical trials in patients with prostate cancer and neuroendocrine tumors.

Approval Year

Doses

Doses

DosePopulationAdverse events​
11070 uCi single, intravenous
Highest studied dose
Dose: 11070 uCi
Route: intravenous
Route: single
Dose: 11070 uCi
Sources:
unhealthy, ADULT
Other AEs: No toxicities were reported...
340 MBq single, intravenous
Recommended
Dose: 340 MBq
Route: intravenous
Route: single
Dose: 340 MBq
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Sources:
Other AEs: No toxicities were reported...
AEs

AEs

AESignificanceDosePopulation
No toxicities were reported
11070 uCi single, intravenous
Highest studied dose
Dose: 11070 uCi
Route: intravenous
Route: single
Dose: 11070 uCi
Sources:
unhealthy, ADULT
No toxicities were reported
340 MBq single, intravenous
Recommended
Dose: 340 MBq
Route: intravenous
Route: single
Dose: 340 MBq
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M
Sources:
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:28:58 GMT 2025
Edited
by admin
on Mon Mar 31 21:28:58 GMT 2025
Record UNII
3934EF02T7
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PIFLUFOLASTAT F18
USAN  
Preferred Name English
PIFLUFOLASTAT F-18
Common Name English
PYLARIFY
Brand Name English
PIFLUFOLASTAT F-18 [ORANGE BOOK]
Common Name English
piflufolastat (¹?F) [INN]
Common Name English
18F-DCFPYL
Common Name English
(18F)DCFPYL
Common Name English
L-GLUTAMIC ACID, N-((((1S)-1-CARBOXY-5-(((6-(FLUORO-18F)-3-PYRIDINYL)CARBONYL)AMINO)PENTYL)AMINO)CARBONYL)-
Systematic Name English
DCFPYL F-18
Common Name English
2-(3-(1-CARBOXY-5-((6-(18F)FLUORO-PYRIDINE-3-CARBONYL)-AMINO)-PENTYL)-UREIDO)-PENTANEDIOIC ACID
Systematic Name English
Piflufolastat (18F) [WHO-DD]
Common Name English
PIFLUFOLASTAT (18F)
INN  
Official Name English
PIFLUFOLASTAT F18 [USAN]
Common Name English
2-(3-(1-CARBOXY-5-((6-(18F) FLUORO-PYRIDINE-3-CARBONYL)-AMINO)-PENTYL)-UREIDO)PENTANEDIOIC ACID
Systematic Name English
Code System Code Type Description
USAN
HI-146
Created by admin on Mon Mar 31 21:28:58 GMT 2025 , Edited by admin on Mon Mar 31 21:28:58 GMT 2025
PRIMARY
FDA UNII
3934EF02T7
Created by admin on Mon Mar 31 21:28:58 GMT 2025 , Edited by admin on Mon Mar 31 21:28:58 GMT 2025
PRIMARY
INN
11870
Created by admin on Mon Mar 31 21:28:58 GMT 2025 , Edited by admin on Mon Mar 31 21:28:58 GMT 2025
PRIMARY
SMS_ID
100000175405
Created by admin on Mon Mar 31 21:28:58 GMT 2025 , Edited by admin on Mon Mar 31 21:28:58 GMT 2025
PRIMARY
NCI_THESAURUS
C116352
Created by admin on Mon Mar 31 21:28:58 GMT 2025 , Edited by admin on Mon Mar 31 21:28:58 GMT 2025
PRIMARY
RXCUI
2556616
Created by admin on Mon Mar 31 21:28:58 GMT 2025 , Edited by admin on Mon Mar 31 21:28:58 GMT 2025
PRIMARY
DRUG BANK
DB14805
Created by admin on Mon Mar 31 21:28:58 GMT 2025 , Edited by admin on Mon Mar 31 21:28:58 GMT 2025
PRIMARY
EVMPD
SUB189818
Created by admin on Mon Mar 31 21:28:58 GMT 2025 , Edited by admin on Mon Mar 31 21:28:58 GMT 2025
PRIMARY
CAS
1207181-29-0
Created by admin on Mon Mar 31 21:28:58 GMT 2025 , Edited by admin on Mon Mar 31 21:28:58 GMT 2025
PRIMARY
PUBCHEM
52950901
Created by admin on Mon Mar 31 21:28:58 GMT 2025 , Edited by admin on Mon Mar 31 21:28:58 GMT 2025
PRIMARY
DAILYMED
3934EF02T7
Created by admin on Mon Mar 31 21:28:58 GMT 2025 , Edited by admin on Mon Mar 31 21:28:58 GMT 2025
PRIMARY
Related Record Type Details
TARGET->RADIOLIGAND
NON-LABELED -> LABELED
Related Record Type Details
ACTIVE MOIETY